Sharon Nachman

CMTx Biotech is a clinical-stage biopharmaceutical company that is developing an orally administered small molecule for the treatment of sepsis patients at risk of Acute Respiratory Distress Syndrome (ARDS) and/or Multiple Organ Dysfunction Syndrome (MODS), including those infected with SARS-CoV-2 (COVID-19).